Pre-clinical development. Immunology and Pharmacology: Inflammation, Immuno-oncology, Cancer, Infectious diseases.

- specialized in the pre-clinical phase of drug development (small molecules, Abs, ADC, vaccines)- functional lead for projects at different stages, from lead candidate selection to IND-enabling studies: propose POC and MOA studies, provide design, implementation and management of studies, deliver data analysis and regulatory reports- experience working in a multidisciplinary, matrix-based set-up- 7+y industry experience

- Pharmacology lead for multiple ADC-development programs (multidisciplinar, matrix-based set-up) for solid and blood cancers (lung, gastro-intestinal and gynecological carcinomas, AML, MDS, DLBCL...).- in vivo pharmacology study design and planning for tolerability,PK/PD and Efficacy studies in xenograft models: implementation, analysis and report for IND-enabling studies.- > Model selection and development of POC studies supporting early candidates development (Discovery phase).-> Design and oversee research determining the compound’s baseline properties: MTD, MED, TI, PK/PD properties and mechanism of action (MOA) for in-development candidates. -> Managed multiple CRO-led studies (Charles River Laboratories, MI Biosciences): MTD and efficacy studies in xenograft and syngeneic cancer models.• Immuno-oncology: Developed several in-house syngeneic allograft models to be used for the pre-clinical package supporting the use of ADCs in combination with check-point inhibitors, in support of ongoing Phase Ib clinical trial.

Managing Potency program for two Genocea Biosciences products currently in Clinical Trials.Development of Functional assays for Vaccine efficiency: - vaccine efficiency modeling in murine model: role of the Th17 response.- assessment of cellular models for surrogate Potency assays: macrophages, lung epithelial cells.Mechanisms of action of vaccine: role of inflammatory cytokines.Immunogenicity (biological) assessment of next generation vaccines.

Managing Potency program for one of our products.In vivo animal models of disease: immunogenicity.Mechansm of action: role of toll-like receptors (TLR2).Collaboration with CRO for Tox study and cGMP-grade potency assays.Scientific communications (poster, peer-reviewed article).

in vivo pharmacology studies: small molecule inhibitors against hematologic malignancies. Studies on Signaling pathways: target validation for PKC, Akt, mTOR small molecule inhibitor candidates. Modeling of myeloproliferative disease in the murine system.Lentiviral siRNA generation and use in mechanism of action studies: role of FoxO3a.Collaborations, reviewer (Blood), peer-reviewed articles, book chapter.

• Study of mechanisms and pathway-based effects of oncogenic growth-factor-receptor (GFR) fusion PTK inducing myeloproliferative diseases in humans. • Engineering of RV vectors used for disease induction in animal model (murine)• In vitro studies of proliferation, cell-cycle and apoptosis and biochemical studies such as target phosphorylation and fusion-kinase activity• drug target validation studies • bone marrow transplants in mice

• Studies on the immune response induced in a mouse model of Toxoplasma gondii (Tg) infection, focus on parasite strain virulence • Discovered increased host cell apoptosis in cases of high virulence strain infection, concomitant with highly increased production of type I inflammatory cytokines• Showed that STAT-1 signaling is not necessary for IFN-gammainduction during Tg infection in STAT-1 KO mice• Extensive in vivo and in vitro experience, with immune-assay based cellular assays executed on primary cells from infected animals• Pioneered and optimized intracellular staining, RNA protection assays and real-time RT-PCR in the Department of Microbiology and Immunology• Participated to multiple scientific meetings in both oral and written form • Initiated the project and created the team or organizers for two Immunology Meetings • Taught in multiple graduate level immunology and parasitology courses• Directed and supervised undergraduate and research assistants’ work

• Cell culture work involved maintaining several melanoma cancer cell-lines• Cellular and biochemical work focused on sub-cellular gradient fractionation, fraction identification and target detection

• Intensive screening of human serum (obtained from allergic patients) in regards to specific allergen responses, using the immuno-electro-focusing technique• Tentative link of the specific allergen response to the HLA type of the patients